-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera appoints oncologists Thomas Lynch, Eric Rubin to board

PUBT·06/03/2026 12:02:23
Listen to the news
Natera appoints oncologists Thomas Lynch, Eric Rubin to board
  • Natera appointed oncology executives Thomas Lynch Jr. and Eric Rubin to its board of directors.
  • Lynch is president and director of Fred Hutch Cancer Center; previously served as CSO at Bristol-Myers Squibb.
  • Rubin was senior vice president of global clinical oncology at Merck; led early development of KEYTRUDA (pembrolizumab).
  • Lynch joined the Human Capital Committee; Rubin joined the Nominating, Corporate Governance and Compliance Committee.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260603829879) on June 03, 2026, and is solely responsible for the information contained therein.